Salarius Pharmaceuticals

Salarius Pharmaceuticals is developing the only reversible lysine specific histone demethylase 1 inhibitors (LSD1) which are close to early clinical studies, expected to start in 2015. Our compound SP-2577 has strong potential to help cancer sufferers in certain sarcomas like Ewing’s sarcoma, acute myeloid leukemia (AML), prostate cancer and triple negative breast cancer and others, where it may be effective in stem-like cancers where many other therapies have failed.